AMRA Medical will be involved in the Facioscapulohumeral Muscular Dystrophy (FSHD) Clinical Trial Research Network (CTRN) to support the Motor Outcomes to Validate Evaluations Plus (MOVE+) study, a natural history study for people living with FSHD.
AMRA's whole-body MRI analysis software will be used in the study to develop biomarkers to better understand disease progression. This involves measuring 36 muscles throughout the participant's shoulders, arms, torso, and legs
The study will enroll 200 participants across 12 sites in the U.S. and two planned sites in Canada with the goal of better understanding how to utilize whole-body MRI to discover and validate specific biomarkers for FSHD that can inform future clinical trials.
